The problem is that people with “normal” or merely “elevated” blood pressure, while at higher risk for cardiovascular disease, stroke, and death than their counterparts with lower blood pressure, are not managed with lifetime prevention and longevity in mind.
There is a significant body of evidence suggesting that lower (sub-normal) blood pressures might help delay the onset of cardiovascular and cerebrovascular disease over the course of a lifetime.
While the data, evidence, and expert opinion is mixed, I believe that it’s important to measure homocysteine levels
In 1978, a pathologist performing a routine autopsy made a remarkable discovery — A 76 year old woman without any sign of atherosclerosis.
What’s so remarkable about this?
The oversimplification of cardiovascular disease risk assessment—in which LDL-cholesterol is often the primary diagnostic, prognostic, and therapeutic target—leads to effective treatment of some people, but the ineffective treatment of others.
For this reason, though it’s very hard to do, I believe we should try to avoid applying guidelines without attention to the particularities of each individual patient.